"In contrast to cfDNA, which is released into the blood when cancer cells die and break apart, CTCs offer a window into the living tumor and the parts that may be resistant to therapy. CTCs can provide information not just on DNA but also on RNA and protein expression and tumor heterogeneity. The problem has been difficulty in harvesting CTCs for analysis. Easy harvest of CTCs is now available using Angle’s Parsortix system. Consequently, there is no longer an advantage in the collection process for cfDNA. Furthermore, both CTCs and cfDNA can now be collected from the same patient sample.”
Peggy Robinson
US Vice President Gen Eng News Article
ANGLE welcomes Axela team and technology, now known as ANGLE Biosciences to the ANGLE group of companies.Read more here